So far, NVS is the only Big Pharma that hasn’t lowered sales and EPS guidance to account for ObamaCare. Why hasn’t it? Simple arithmetic: 60% of NVS’ sales come from the pharma division and only one-third half of that comes from the US
The other side of the coin - NVS is much more exposed to Europe/Euro and might face headwind from the crisis there.
Market Data 
Markets 
AI
